Literature DB >> 7777295

5-Fluorouracil filtering surgery and neovascular glaucoma. Long-term follow-up of the original pilot study.

J C Tsai1, W J Feuer, R K Parrish, A L Grajewski.   

Abstract

BACKGROUND: The long-term efficacy and safety of filtering surgery with 5-fluorouracil (5-FU) in eyes with neovascular glaucoma are unknown.
METHODS: Kaplan-Meier survival curve analysis of surgical outcome was performed on all 34 patients (34 eyes) enrolled from May 1982 through April 1986 in the original pilot study of filtering surgery with 5-FU.
RESULTS: Success rates at the 1-, 2-, 3-, 4-, and 5-year intervals were 71%, 67%, 61%, 41%, and 28%, respectively. The median filter survival time was 38.7 months (95% confidence interval: 32-45 months). Twelve (35%) of 34 patients lost light perception vision, and phthisis bulbi developed in 8 (24%) of 34 patients. Age of 50 years or younger (P < 0.0001) and type 1 diabetes (P = 0.0004) were significant risk factors for surgical failure. The 1-year success rate for patients no older than 50 years of age was 23% compared with a 95% success rate in patients older than 50 years of age. After adjustment for age, type 1 diabetes was a borderline risk factor (P = 0.06).
CONCLUSION: There is a high risk of long-term failure of filtering surgery with 5-FU in neovascular glaucoma. Patients 50 years of age or younger have an extremely poor prognosis. Patients older than 50 years of age have initial short-term success with an accelerated failure rate after 3 years.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7777295     DOI: 10.1016/s0161-6420(95)30938-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

Review 1.  Medical and surgical treatment of neovascular glaucoma.

Authors:  Lisa C Olmos; Richard K Lee
Journal:  Int Ophthalmol Clin       Date:  2011

2.  Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma.

Authors:  Yoshiaki Kiuchi; Kazuto Nakae; Yoshihiro Saito; Shigeo Ito; Nami Ito
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

3.  Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab.

Authors:  L C Olmos; M S Sayed; A L Moraczewski; S J Gedde; P J Rosenfeld; W Shi; W J Feuer; R K Lee
Journal:  Eye (Lond)       Date:  2015-12-18       Impact factor: 3.775

4.  Comparison of 90-s versus 5-min intraoperative 5-fluorouracil in trabeculectomy.

Authors:  Andrea Zarkovic; Kent Chow; Justin S Mora
Journal:  Int Ophthalmol       Date:  2009-01-10       Impact factor: 2.031

Review 5.  Anti-vascular endothelial growth factor for neovascular glaucoma.

Authors:  Arathi Simha; Andrew Braganza; Lekha Abraham; Prasanna Samuel; Kristina Lindsley
Journal:  Cochrane Database Syst Rev       Date:  2013-10-02

6.  Risk factors for failures of trabeculectomies performed without antimetabolites.

Authors:  H Mietz; B Raschka; G K Krieglstein
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

7.  The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).

Authors:  Peter A Netland
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

8.  Intravitreal bevacizumab for neovascular glaucoma.

Authors:  Deepta Vasudev; Michael P Blair; John Galasso; Rashmi Kapur; Thasarat Vajaranant
Journal:  J Ocul Pharmacol Ther       Date:  2009-10       Impact factor: 2.671

9.  Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma.

Authors:  Christopher C Shen; Sarwat Salim; Haiming Du; Peter A Netland
Journal:  Clin Ophthalmol       Date:  2011-03-01

10.  Efficacy and Safety of Combined Surgeries including Intraocular Direct Cyclophotocoagulation with a 532 nm Laser to Treat Advanced Neovascular Glaucoma.

Authors:  Xiaomin Chen; Tian Zheng; Wen Zeng; Xia Fu; Shun Wang; Weijuan Zeng; Min Ke
Journal:  J Ophthalmol       Date:  2021-07-07       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.